ATE236993T1 - Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper - Google Patents

Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper

Info

Publication number
ATE236993T1
ATE236993T1 AT95938608T AT95938608T ATE236993T1 AT E236993 T1 ATE236993 T1 AT E236993T1 AT 95938608 T AT95938608 T AT 95938608T AT 95938608 T AT95938608 T AT 95938608T AT E236993 T1 ATE236993 T1 AT E236993T1
Authority
AT
Austria
Prior art keywords
von willebrand
willebrand factor
monoclonal antibodies
directed against
antibodies directed
Prior art date
Application number
AT95938608T
Other languages
English (en)
Inventor
Mitsuyo Nagano
Hiroshi Yamamoto
Morikazu Kito
Ryota Yoshimoto
Tsuyoshi Kobayashi
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE236993T1 publication Critical patent/ATE236993T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95938608T 1994-11-30 1995-11-29 Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper ATE236993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29707094 1994-11-30
PCT/JP1995/002435 WO1996017078A1 (en) 1994-11-30 1995-11-29 Antithrombotic agent and anti-von willebrand factor monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE236993T1 true ATE236993T1 (de) 2003-04-15

Family

ID=17841828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938608T ATE236993T1 (de) 1994-11-30 1995-11-29 Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper

Country Status (13)

Country Link
US (3) US5916805A (de)
EP (1) EP0795608B1 (de)
JP (1) JP3331377B2 (de)
KR (1) KR100406072B1 (de)
CN (1) CN1254275C (de)
AT (1) ATE236993T1 (de)
DE (1) DE69530316T2 (de)
DK (1) DK0795608T3 (de)
ES (1) ES2197210T3 (de)
FI (1) FI119734B (de)
NO (1) NO319738B1 (de)
PT (1) PT795608E (de)
WO (1) WO1996017078A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916805A (en) 1994-11-30 1999-06-29 Ajinomoto Co., Inc. Antithrombotic agent and anti-von Willebrand factor monoclonal antibody
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6251393B1 (en) 1998-10-23 2001-06-26 The Brigham And Women's Hospital, Inc. Conformation-specific anti-von Willebrand Factor antibodies
CN1198198C (zh) * 2001-02-27 2005-04-20 索尼公司 字符输入方法及字符输入装置
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
JPWO2004011030A1 (ja) * 2002-07-29 2005-11-24 味の素株式会社 血小板減少症治療用医薬組成物
AU2003251238A1 (en) * 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
AU2003283137B8 (en) * 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
EP2284192A3 (de) * 2002-11-08 2011-07-20 Ablynx N.V. Antikörper aus Camelidae zur sublingualen Verabreichung
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
ES2551682T3 (es) * 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
NZ576284A (en) * 2003-01-10 2010-07-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
MXPA05006043A (es) * 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
CN1323713C (zh) * 2003-07-07 2007-07-04 张新侯 可溶性p-选择素及炭疽致死毒素的新用途
WO2006029258A2 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
SG156618A1 (en) 2004-09-07 2009-11-26 Archemix Corp Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
TR201815552T4 (tr) 2005-05-20 2018-11-21 Ablynx Nv Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
EP1958626B1 (de) 2007-02-13 2014-07-23 Ajinomoto Co., Inc. Verfahren zur Inaktivierung von Viren durch Zusatz von leicht saurem Arginin
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
EP2281827B1 (de) 2008-05-08 2013-08-21 Ajinomoto Co., Inc. Verfahren zur rückfaltung einer proteinstruktur
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
CN103608463A (zh) 2011-06-23 2014-02-26 味之素株式会社 由使具有免疫球蛋白折叠结构的蛋白和能够形成亚单元结构的蛋白融合而得到的单体蛋白组成的多聚体蛋白的制备方法
ES2670991T3 (es) * 2013-12-18 2018-06-04 Siemens Healthcare Diagnostics Inc. Detección de enfermedad endotelial
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
MX2022000133A (es) 2019-07-01 2022-04-27 Tonix Pharma Ltd Anticuerpos anti-cd154 y usos de los mismos.
WO2021118845A1 (en) * 2019-12-12 2021-06-17 Corning Incorporated Light-diffusing element configured to affect thrombi formation on intravenous catheter
WO2022150452A1 (en) 2021-01-06 2022-07-14 Seth Lederman Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202264A (en) * 1989-10-27 1993-04-13 Health Research, Incorporated ELISA using multi-species antibodies for detection of von Willebrand factor in multiple species
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
US5916805A (en) * 1994-11-30 1999-06-29 Ajinomoto Co., Inc. Antithrombotic agent and anti-von Willebrand factor monoclonal antibody
AU724579B2 (en) 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor

Also Published As

Publication number Publication date
NO972253L (no) 1997-07-29
US6793920B2 (en) 2004-09-21
DE69530316D1 (de) 2003-05-15
US20020028204A1 (en) 2002-03-07
EP0795608A1 (de) 1997-09-17
US6280731B1 (en) 2001-08-28
FI119734B (fi) 2009-02-27
FI972279L (fi) 1997-07-29
PT795608E (pt) 2003-08-29
US5916805A (en) 1999-06-29
DE69530316T2 (de) 2004-02-12
ES2197210T3 (es) 2004-01-01
DK0795608T3 (da) 2003-07-21
WO1996017078A1 (en) 1996-06-06
FI972279A0 (fi) 1997-05-29
CN1254275C (zh) 2006-05-03
EP0795608B1 (de) 2003-04-09
CN1174575A (zh) 1998-02-25
KR100406072B1 (ko) 2004-03-30
JP3331377B2 (ja) 2002-10-07
EP0795608A4 (de) 2001-11-28
NO319738B1 (no) 2005-09-12
NO972253D0 (no) 1997-05-16

Similar Documents

Publication Publication Date Title
ATE236993T1 (de) Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
RU94046294A (ru) Стероидные гликозиды для лечения гиперхолестеринэмии
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
BR9406025A (pt) Composição para barbear não de aerossol
FI925098A7 (fi) Ihmisen papilloomavirusten 1,5,6,8,11,16,18,31,33 ja 56 synteettisiä p eptidejä, jotka ovat käyttökelpoisia immunoanalyysissä diagnostisiin t arkoituksiin
ATE283704T1 (de) Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom
IT1281188B1 (it) Composizione per prevenire e trattare infiammazioni con immunoglobulina a.
SE9401540D0 (sv) Munhygienkomposition
ATE83376T1 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
BR9509975A (pt) Formulação farmacêutica
DE60237447D1 (de) Verwendung von polyklonalen anti-hiv ziegenseren als therapeutisches mittel
SE9402880D0 (sv) New peptide derivatives
EP0693067A4 (de) Fibrinogenrezeptorantagonisten
KR930019224A (ko) 유산 위험 치료제
DK0437225T3 (da) Topiske præparater
FI883723A7 (fi) Ihmisen monoklonaaliset vasta-aineet ja niitä vaikuttavana aineosana s isältävät terapeuttiset aineet infektiotauteja vastaan
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
CA2206423A1 (en) Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
DK0663832T3 (da) Anvendelse af 4'-iod-4'-deoxydoxorubicin til behandling af amyloidose
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
SE9401596D0 (sv) New compounds
FR2601950B1 (fr) N,n-dimethyl-n'-benzoyl-n' ((2,3-dihydro) benzofuran-2-yl-methyl) 1,3-propanediamine, preparation et compositions pharmaceutiques les contenant
RU93055153A (ru) Антибактериальное средство "анальгин"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0795608

Country of ref document: EP